Takeda Reports Changes in Subsidiaries and Associates as of May 28, 2025

Takeda Pharmaceutical Company ( (TAK) ) has shared an announcement.

On May 28, 2025, Takeda Pharmaceutical Company Limited reported changes in its consolidated subsidiaries and associates. The company increased its number of consolidated subsidiaries by two due to establishment, while decreasing by thirteen mainly due to liquidation and merger. Additionally, the number of associates accounted for using the equity method increased by three and decreased by four, primarily due to divestiture and changes in ownership ratios. These adjustments reflect Takeda’s ongoing strategic realignment and optimization of its business operations, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (TAK) stock is a Hold with a $13.40 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Company stock, see the TAK Stock Forecast page.

Spark’s Take on TAK Stock

According to Spark, TipRanks’ AI Analyst, TAK is a Outperform.

Takeda Pharmaceutical Company demonstrates strong financial performance, driven by consistent revenue and profit growth, a solid balance sheet, and effective cash flow management. While the company’s technical indicators show moderate bullish momentum, the high P/E ratio raises valuation concerns. The mixed earnings call highlights both promising product launches and challenges from generic competition. Overall, Takeda’s strong fundamentals and promising pipeline are somewhat tempered by valuation and competitive pressures, resulting in an overall stock score of 71.

To see Spark’s full report on TAK stock, click here.

More about Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Tokyo, Japan. It operates in the healthcare industry, focusing on the development, manufacturing, and marketing of pharmaceutical products. Takeda’s primary products include prescription medications across various therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases. The company has a significant market presence in both developed and emerging markets.

Average Trading Volume: 2,140,681

Technical Sentiment Signal: Buy

Current Market Cap: $46.12B

See more insights into TAK stock on TipRanks’ Stock Analysis page.